Method
Level · gp.fundamentals.debt_to_revenue
Raw value 20460.82% · OPTIONAL
· Biological Products, (No Diagnostic Substances)
RESEARCH SNAPSHOTBeam Therapeutics Inc.'s latest supported as-filed period reports revenue of $490,000, 94.2% below the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.debt_to_revenue
Raw value 20460.82% · OPTIONAL
Level · gp.fundamentals.capex_revenue_ratio
Raw value 492.65% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -13488.98% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value -94.21% · CORE
Level · gp.fundamentals.operating_margin
Raw value -25827.14% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 19407.35% · OPTIONAL
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed -22.1% from the comparable as-filed period.
Net income changed -19.9% from the comparable as-filed period.
Operating income changed -5.3% from the comparable as-filed period.
Operating margin changed -2440792 basis points from the comparable as-filed period.
Each point keeps the date investors could first observe it and its accession.
BEAM · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-331541SEC ↗8-KAug 4, 2026Period Aug 4, 20260001193125-26-331522SEC ↗4Jul 29, 2026Period Jul 27, 20260001193125-26-323640SEC ↗4Jul 2, 2026Period Jun 30, 20260001193125-26-294478SEC ↗4Jul 1, 2026Period Jun 29, 20260001193125-26-292526SEC ↗4Jun 29, 2026Period Jun 25, 20260001193125-26-288078SEC ↗4Jun 22, 2026Period Jun 17, 20260001193125-26-277509SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jul 27, 2026Filed Jul 29, 2026 | Simon AmyChief Medical Officer | Open Market SaleDirect | 16,667 | $26 | $429,037 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Level · gp.fundamentals.sbc_revenue_ratio
Raw value 3934.29% · OPTIONAL
Research & development changed -6.5% from the comparable as-filed period.
Revenue changed -94.2% from the comparable as-filed period.
Stock-based compensation changed -20.9% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-261693